Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 40 of 40 results for bph

  1. Lower urinary tract symptoms secondary to benign prostatic hyperplasia: tadalafil (ESNM18)

    This evidence summary has been updated and replaced by NICE guideline CG97.

    Withdrawn advice

  2. Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia (MTG49)

    We have moved Medical technologies guidance 49 to become HealthTech guidance 545. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  3. Transperineal laser ablation for treating lower urinary tract symptoms of benign prostatic hyperplasia (IPG798)

    We have moved interventional procedures guidance 798 to become HealthTech guidance 737. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  4. Prostate artery embolisation for lower urinary tract symptoms caused by benign prostatic hyperplasia (IPG611)

    We have moved interventional procedures guidance 611 to become HealthTech guidance 469. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  5. Transurethral water-jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia (IPG770)

    We have moved interventional procedures guidance 770 to become HealthTech guidance 691. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  6. Transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia (IPG625)

    We have moved interventional procedures guidance 625 to become HealthTech guidance 482. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  7. Transurethral water jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia (IPG629)

    This guidance has been updated and replaced by NICE HealthTech guidance 691.

    Withdrawn guidance

  8. Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia (IPG737)

    We have moved interventional procedures guidance 737 to become HealthTech guidance 639. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  9. Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia (IPG641)

    This guidance has been updated and replaced by HealthTech guidance 639.

    Withdrawn guidance

  10. Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia (IPG475)

    We have moved interventional procedures guidance 475 to become HealthTech guidance 329. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance